The survey aimed at evaluating the quality of selected antimalarials in six
countries of sub-Saharan Africa (Cameroon, Ethiopia, Ghana, Kenya, Nigeria and the United Republic of Tanzania).
These countries have been supported by WHO to strengthen their regulatory controls over antimalarial
products. The survey was organized independently of manufacturers of antimalarial medicines...Of 306
samples selected for laboratory testing, 267 were fully tested and 28.5% of them
failed to comply with specifications. Although non-compliance with pre-established criteria
cannot be directly related to a risk for patients' health, such a high failure rate indicates a substantial problem
in the quality of antimalarials present in distribution channels. Focusing only on extreme deviations from
specifications (as defined in this report), which are likely to be associated with health implications, the failure
rate reached 11.6%...